Incretin analogs and their use
The incretin analog with optimized amino acid sequences and fatty acid modifications addresses the limitations of current incretins by enhancing receptor binding and stability, effectively managing obesity and diabetes.
JP2025525218AActive Publication Date: 2025-08-01SHANGHAI MINWEI BIOTECHNOLOGY CO LTD
3 Cites 0 Cited by
Patent Information
- Application Number
- JP2025506104
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-23
- Filing Date
- 2024-03-20
- Publication Date
- 2025-08-01
- Estimated Expiration
- 2044-03-20
AI Technical Summary
Technical Problem
Current incretin analogs with GLP-1R/GIPR/GCGR triple agonistic activity have deficiencies in terms of structure, activity, stability, and production cost, limiting their effectiveness in treating obesity and diabetes.
Method used
Development of an incretin analog with specific amino acid sequences and fatty acid chain modifications that enhance binding and activation of GLP-1R, GIPR, and GCGR receptors, improving biological activity, stability, and reducing immunogenicity and production costs.
Benefits of technology
The incretin analog demonstrates enhanced GLP-1, GCG, and GIP triple activities, significantly reducing body weight, body fat, blood glucose, and cholesterol levels, and improving liver function, with improved stability and lower production costs.
✦ Generated by Eureka AI based on patent content.
Abstract
Incretin analogs and their use. It contains a triple-acting agent protein for human glucose-dependent insulinotropic polypeptide (GIP) receptor, glucagon-like peptide-1 (GLP-1) receptor and glucagon (GCG) receptor, and is useful for the treatment of type 2 diabetes (T2D), obesity, non-alcoholic fatty liver disease (NAFLD) and other carbohydrate and lipid metabolism disorders.
Need to check novelty before this filing date? Find Prior Art